Why does null hypothesis testing matter for neutralization assay target validation?

Null hypothesis testing in the neutralization assay quantifies whether observed reductions in viral entry are statistically significant, supporting robust target validation for antibody-mediated inhibition. This ensures that candidate antibodies or sera demonstrate true neutralizing activity beyond baseline variability. Such rigor underpins confidence in advancing immunotherapeutic leads.

How does independent variable isolation fit the pseudovirus neutralization workflow?

By controlling serum dilution and pseudovirus input, the assay isolates the effect of specific antibodies on viral entry, enabling mechanistic de-risking. This isolation clarifies the contribution of humoral immunity and informs early-stage candidate selection. It supports reproducible, interpretable outputs for cross-study comparison.

What do quantitative luminescence measurements enable in serum neutralization testing?

Quantitative luminescence readouts provide a direct, scalable measure of viral entry inhibition, allowing precise comparison of neutralizing activity across samples. These outputs facilitate statistical analysis and threshold setting for immune potency. They are essential for high-throughput screening and portfolio triage.

Why are replication requirements critical for cross-functional neutralization assay collaboration?

Replication ensures assay reproducibility and data reliability, which are vital for cross-team decision-making and downstream development. Consistent results across replicates support confidence in candidate advancement and facilitate regulatory and translational alignment. This underpins enterprise-wide assay adoption.

What statistical analysis capabilities are required before implementing pseudovirus neutralization assays?

Robust statistical analysis is needed to interpret luminescence data, determine neutralization thresholds, and validate assay performance. Capabilities should include calculation of percent neutralization, curve fitting, and significance testing. These analyses support data-driven advancement decisions in immunotherapy pipelines.

Virus pseudotipizzati come strumento molecolare per monitorare le risposte immunitarie umorali contro SARS-CoV-2 tramite test di neutralizzazione

2.9K visualizzazioni

05:49 min

21 novembre 2023

10.3791/65658-v

21 novembre 2023

2.9K visualizzazioni

Tobia Fantoni^*¹ , Michele Bissoli^*¹ , Chiara Stefani¹ , Mauro Voi¹ , Alexandrina Dabija¹ , Rebecca Casula¹ , Domenico Luca Minafra¹ , Julys da Fonseca Palmeira² , Enrique Roberto Argañaraz² , Martin Mayora-Neto³ , Nigel J. Temperton³ , Donato Zipeto¹ , Alessandra Ruggiero¹

¹Department of Neuroscience, Biomedicine and Movement, University of Verona, ²Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Brasília, ³Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich at Medway

^* These authors contributed equally

I virus pseudotipizzati (PV) sono virioni difettosi di replicazione che vengono utilizzati per studiare le interazioni ospite-virus in condizioni più sicure rispetto alla manipolazione di virus autentici. Di seguito è presentato un protocollo dettagliato che mostra come i PV SARS-CoV-2 possono essere utilizzati per testare la capacità neutralizzante del siero dei pazienti dopo la vaccinazione COVID-19.